Archive


Category: ACEA

  • Sorrento to Acquire ACEA Therapeutics for ~$488M

    Shots: ACEA to receive up to ~$38M in shares of Sorrento common stock, $450M as additional payments upon the achievement of clinical & sales milestones along with 5 – 10% royalties based on annual sales of each product. The acquisition is expected to close in Q2’ 21 The acquisition includes Abivertinib, AC0058, AC0939, and ACEA’s […]